



24 April 2015
EMA/264729/2015
Human Medicines Evaluation Division

Overview of (invented) names reviewed in March 2015 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 20-23 April 2015

	NRG meeting		NRG meeting		NRG meeting		NRG meeting		NRG meeting		NRG meeting		2015	
	28 Jan 2015		25 Mar 2015		20 May 2015		01 Jul 2015		30 Sep 2015		25 Nov 2015			
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed (invented) names	26	22	22	27										
Justification for retention of (invented) name *	4	2	3	1										

*In case of objections to the proposed (invented) name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.



	NRG meeting 28 Jan 2015		NRG meeting 25 Mar 2015		NRG meeting 20 May 2015		NRG meeting 01 Jul 2015		NRG meeting 30 Sep 2015		NRG meeting 25 Nov 2015		2015	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Total number of objections raised	45	25	53	53										
Criterion - Safety concerns														
Similarity with other (invented) name	25	23	34	49										
Conveys misleading therapeutic/pharmaceutical connotations	4	0	4	0										
Misleading with respect to composition	7	1	3	2										
Criterion - INN concerns														
Similarity with INN	0	1	1	0										
Inclusion of INN stem	0	0	2	1										
Criterion - Other public health concerns														
Unacceptable qualifiers	6	0	4	0										
Conveys a promotional message	1	0	2	1										
Appears offensive or has an inappropriate connotation	1	0	3	0										
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	0	0	0	0										
Similarity between name of prodrug and related active substance	0	0	0	0										
Others	1	0	0	0										

See *Guideline on the Acceptability of Names for Human Medicinal Products Processed through the Centralised Procedure (EMA/CHMP/287710/2014)* for detailed explanations of criteria used.